UPB · Upstream Bio, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on UPB. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About UPB · Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Live Quote
SELL (score -4) · 12-1 mom -25.7% · RSI 34.2 · below_both · -80.6% from high
Targets blend Wall Street consensus (8 analysts: low $8.00 / mean $38.25 / high $75.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
All 10 Form 4 filings in the past 14 days are either sell-to-cover (S code) for automatic RSU tax withholding or new director option grants (A code). None represent discretionary open-market purchases. The triggering signal was based on volume of filings, not genuine insider conviction buying. UPB experienced an ~80% crash in February 2026 after the Phase 2 VALIANT asthma readout — market participants reacted negatively to what appeared to be a miss versus elevated expectations despite nominally positive data. The stock trades at $6.15 with no near-term catalyst (Phase 3 initiation Q1 2027, data years away), deeply negative FCF of ~$90M/quarter in clinical-stage burn, and an oversold technical picture that offers mean-reversion hope but no fundamental re-rating trigger within the investment window.